Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer.

ABSTRACT:

Background

During tumor progression, HER2 expression undergoes dynamic changes. Circulating tumor cells (CTCs) can be used to monitor HER2 expression in real-time and hold potential for clinical application. This study aimed to evaluate the consistency of HER2 expression between primary tumors and CTCs in patients with breast cancer (BC).

Methods

We used a previously established telomerase reverse transcriptase-based CTC detection method (TBCD) combined with anti-HER2 antibody to detect CTC and HER2-positive CTC (HER2 + CTC) in 4 ml of peripheral blood from patients with breast cancer prior to radiotherapy. The results indicated that the status of HER2 in CTC was inconsistent with the histological results.

Results

Discordance in HER2 status between primary tumor and C

SUBMITTER: Xie P 

PROVIDER: S-EPMC11655891 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature